|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 409/06 | |
| C07D 207/26 | |||
| C07D 207/273 | |||
| A61K 31/4015 | |||
| A61K 31/4025 | |||
| A61P 27/02 | |||
| A61P 27/06 | |||
| A61P 25/02 | |||
| A61P 17/14 | |||
| A61P 19/10 |
| (11) | Number of the document | 3176162 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16192438.6 |
| Date of filing the European patent application | 2013-07-19 | |
| (97) | Date of publication of the European application | 2017-06-07 |
| (45) | Date of publication and mention of the grant of the patent | 2020-05-27 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201261673514 P | 2012-07-19 | US | |
| 201361793929 P | 2013-03-15 | US |
| (72) |
BARRETT, Stephen Douglas, US
CISKE, Fred Lawrence, US
COLOMBO, Joseph Michael, US
ENDRES, Gregory William, US
GERMAIN, Bradlee David, US
KORNILOV, Andriy, US
KRAMER, James Bernard, US
UZIEBLO, Adam, US
MAXEY, Kirk M., US
|
| (73) |
Cayman Chemical Company, Inc.,
1180 E. Ellsworth Road, Ann Arbor, Michigan 48108,
US
|
| (54) | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS |
| DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS |